Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy

Inclusion Criteria:

* Subjects have metastatic TNBC
* Disease suitable for analysis from either (a) or (b) below:

  * (a) Research biopsy

    * Tumor tissue, which can include bone disease, as determined by physical exam or imaging (as assessed by a trained specialist in radiology)
    * Must be collected before the subject receives treatment with a drug they have not received previously
  * (b) Standard of care biopsy

    * Tumor tissue available from a previous biopsy as standard of care (to be determined by the principal investigator \[PI\] or his designee)
    * Must have been collected before subject receives treatment with a drug they have not received previously
    * May begin treatment either after enrollment or within several weeks prior to enrollment
* Subjects must be medically fit and willing to undergo repeated tissue biopsies or surgical procedures to get tumor tissue
* Procedure-specific signed informed consent prior to initiation of any study-related procedures
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (or a Karnofsky performance status of \>= 50%)
* Agree to allow their de-identified clinical and laboratory data to be posted to publicly available databases such as database of Genotypes and Phenotypes (dbGaP)

Exclusion Criteria:

* Bevacizumab treatment within 4 weeks prior to biopsy
* Anticoagulation therapy, unless reversed at the time of biopsy
* The enrolling study oncologist has decided that the subject is not fit enough to undergo repeated tissue biopsies
* Presence of a condition or abnormality that in the opinion of the enrolling investigator would compromise the safety of the subject or the quality of the data
* Significant bleeding disorder
* Known brain metastases that have not or will not be treated
* Subjects with a life expectancy of less than 6 months
* Prisoners
* Inability to give informed consent